Axial Spondyloarthritis (AxSpA): Competitive Landscape to 2026

Axial Spondyloarthritis (AxSpA): Competitive Landscape to 2026

Summary

AxSpA is a chronic, immune-mediated inflammatory disease of the axial skeleton (sacroiliac joints and spine). It is characterized by a polyenthesitis, which at the molecular level leads to an osteitis and secondary synovitis. AxSpA is an umbrella term that includes ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-AxSpA). In some cases, nr-AxSpA is the earlier form of the disease and may progress to AS.

This report provides an assessment of the pipeline, clinical, and commercial landscape of AxSpA. Overall, it expects new drug approvals, including interleukin 17 inhibitors, to drive AxSpA market growth over the next decade (2016-2026).

Scope

- Axial Spondyloarthritis (AxSpA): Competitive Landscape to 2026 combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace. Components of the slide deck include -
- Pipeline Assessment: regional breakdown, promising late-stage products, early-stage pipeline by molecule type
- Clinical Trials Assessment: trial breakdown by phase, leading industry and non-industry sponsors, enrollment analytics
- Commercial Assessment: leading marketed products, current and future players
- Competitive Landscape Analysis: key market events (2016-2026).

Reasons to buy

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global AxSpA market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global AxSpA market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

1. Preface 2
1. 2
1.2 Abbreviations 3
1.3 Related Reports 4
1.4 Upcoming Related Reports 5
2. Executive Summary 6
2.1 Key Findings 7
2.2 Key Events 8
3. Introduction 9
3.1 Report Scope 10
3.2 Disease Overview and Epidemiology 12
4. Pipeline Assessment 16
4.1 Pipeline Overview 17
4.2 Pipeline Breakdown by Region/Country 19
4.3 Pipeline Breakdown by Molecule Type and Target 20
4.4 Drug Review Designations 21
4.5 Products in Clinical Development 22
5. Clinical Trials Assessment 24
5.1 Clinical Trials Overview 25
5.2 Top Sponsors of Clinical Trials in AxSpA 26
5.3 Trial Breakdown by Region 28
5.4 Therapy Area Perspective 30
5.5 Enrollment Analytics 31
6 Commercial Assessment 34
6.1 Leading Marketed Products 35
6.2 Current & Future Players 36
7. Competitive Landscape Analysis (2016-2026) 37
7.1 Events Classification Overview 38
7.2 US 39
7.3 5EU 40
7.4 Japan 41
7.5 Australia 42
8 Appendix 43
8.1 Sources 44
8.2 Methodology 45
8.3 Key Events Included in the Analysis 46
8.4 About the Authors 47
8.5 About GlobalData 50
8.6 Disclaimer 52

Axial Spondyloarthritis (AxSpA): Competitive Landscape to 2026

Axial Spondyloarthritis (AxSpA): Competitive Landscape to 2026AxSpA is a chronic, immune-mediated inflammatory disease of the axial skeleton (sacroiliac joints and spine). It is characterized by a polyenthesitis, which at the

USD 3495 View Report

Axial Spondyloarthritis - Pipeline Review, H1 2018

Axial Spondyloarthritis - Pipeline Review, H1 2018Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Axial Spondyloarthritis - Pipeline Review, H1 2018, provides an overview of the Axial Spondyloarthritis

USD 2000 View Report

Axial Spondyloarthritis - Pipeline Review, H1 2018

Axial Spondyloarthritis - Pipeline Review, H1 2018Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Axial Spondyloarthritis - Pipeline Review, H1 2018, provides an overview of the Axial Spondyloarthritis

USD 2000 View Report

Axial Spondyloarthritis - Pipeline Insight, 2018

Axial Spondyloarthritis - Pipeline Insight, 2018 report by DelveInsight offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Axial Spondyloarthritis development. The report provides detailed

USD 1250 View Report

Your are not allow to send sample request

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available